Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Anti-CTLA4 Blockade With Ipilimumab in Patients With AJCC Stage IIIB-C (Tx,1-4, N1b,2b, 2c, 3, M0) Melanoma: Immunogenicity And Biomarker Analysis

NCT00972933 is registered in ClinicalTrials.gov with Diwakar Davar as lead sponsor.

NCT NCT00972933
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00972933 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Anti-CTLA4 Blockade With Ipilimumab in Patients With AJCC Stage IIIB-C (Tx,1-4, N1b,2b, 2c, 3, M0) Melanoma: Immunogenicity And Biomarker Analysis
Lead sponsor
Diwakar Davar
Phase
Phase 1
Overall status
Completed
Start date
December 31, 2009
Completion date
September 26, 2017
Enrollment
59 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma